title: Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate).
abstract: The recommended regimen of etidronic acid (disodium etidronate) for the treatment of Paget's disease of bone is 5mg/kg/day for a period of less than six months. There have, however, been reports of impaired mineralisation of bone and concern that the risk of fracture is increased with this dosage. We report a patient with Paget's disease in whom fractures occurred through pagetic and non-pagetic bone which appeared to be causally related to treatment with lose doses of etidronic acid. The osteomalacia resolved when etidronic acid was discontinued.
authors.affiliation: WHO Collaborating Centre for Metabolic Bone Diseases, Department of Human Metabolism, University of Sheffield, England.
authors.forename: K S
authors.initials: KS
authors.lastname: Eyres
authors.forename: P
authors.initials: P
authors.lastname: Marshall
authors.forename: E
authors.initials: E
authors.lastname: McCloskey
authors.forename: D L
authors.initials: DL
authors.lastname: Douglas
authors.forename: J A
authors.initials: JA
authors.lastname: Kanis
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D012968:Etidronic Acid / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005265:Femoral Neck Fractures / Q000209:etiology; D005598:Fractures, Spontaneous / Q000209:etiology*; D006801:Humans; D010001:Osteitis Deformans / Q000188:drug therapy*; D010018:Osteomalacia / Q000139:chemically induced / Q000150:complications; D013978:Tibial Fractures / Q000209:etiology
chemical_list: D012968:Etidronic Acid